Home / Products / Lenvat 4mg Tablets | 120-Count | LENVATINIB
Oncology & Cancer Care Pharma
Lenvat 4mg Tablets | 120-Count | LENVATINIB
$290
For in vitro laboratory research only. Not for human or veterinary consumption.
India Warehouse LENVATINIB — 4mg per tablet, 120-count pack. Multi-kinase inhibitor for differentiated thyroid cancer, hepatocellular carcinoma (HCC), endometrial carcinoma (with pembrolizumab), and renal cell carcinoma. Key warning: Blood pressure monitoring from day 1. Hepatotoxicity monitoring. Hold 1 week before surgery. Embryofetal toxicity. QT prolongation monitoring.
SKU VES-003909-LENVAT-4MG-120TAB
Format N/A
Use Laboratory research only
Product information
Specifications and research context What is Lenvat 4mg (LENVATINIB)? Multi-kinase inhibitor for differentiated thyroid cancer, hepatocellular carcinoma (HCC), endometrial carcinoma (with pembrolizumab), and renal cell carcinoma.
How it Works Inhibits VEGFR1-3, FGFR1-4, PDGFRalpha, KIT, and RET kinases — broadly blocks tumor angiogenesis and proliferative signaling.
Quick Specs
Form Oral tablets — pre-dosed
Active Ingredient LENVATINIB
Dose per Tablet 4MG
Pack Size 12×10 (120 tablets)
Storage Room temperature (15–25°C), cool dry place
Shelf Life 2–3 years (properly stored) Common Side Effects Hypertension (very common), fatigue, diarrhea, decreased appetite, nausea, hand-foot syndrome, proteinuria, hepatotoxicity.
Safety Warnings Blood pressure monitoring from day 1. Hepatotoxicity monitoring. Hold 1 week before surgery. Embryofetal toxicity. QT prolongation monitoring. International shipping: 7–14 days
Research use only This material is supplied strictly for in vitro laboratory research. It is not intended for human or veterinary consumption, diagnosis, treatment, or household use.
